PRGOPRGOHealthcare · Drug Manufacturers - Specialty & Generic

PRGO Stock Forecast: Perrigo Co. Plc Price Predictions for 2026-2027

Last close, 18 Nov 2026
$17
+7.49% on the day

The 4 Wall Street analysts covering Perrigo Co. Plc hold a median 12-month price target of $19 — +12.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 17 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.2B
Ticker Nerd rank
90/ 100
Median analyst target
$19
Analysts covering
4
Revenue$1.0B−3.2% y/y
Operating income$39.0M
Net income$74.4M
Free cash flow$68.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.4%
1M
+1.9%
YTD
+30.1%
1Y
+35.2%
From 52W high
−0.1%
From 52W low
+91.6%
$9
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRGO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Perrigo Co. Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
90/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
98
Value
98
Issuance
85
Volatility
84
Revisions
78
Quality
65
Momentum
56
Size
33
Growth
25

Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (25): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PRGO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRGO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$8$10$12$14$16$18$20Jan 26Apr 26Jul 26Oct 26PRGOHigh $20Median $19Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
1 Buy3 Hold0 Sell
Low $15Median $19High $20

The green dot is the last close — the median target sits +12.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Oct 2026Canaccord GenuityMaintainsBuy—
30 Oct 2026Canaccord GenuityMaintainsBuy$17 → $19
27 Feb 2026Canaccord GenuityMaintainsBuy—
27 Feb 2026Canaccord GenuityMaintainsBuy$20 → $17
15 Dec 2025JP MorganMaintainsNeutral—
6 Nov 2025Canaccord GenuityMaintainsBuy—
6 Nov 2025JP MorganDowngradeNeutral—
27 Oct 2025JefferiesMaintainsHold—
7 Aug 2025Canaccord GenuityMaintainsBuy—
7 Aug 2025JP MorganMaintainsOverweight—
6 Jan 2025Piper SandlerDowngradeNeutral—
30 Sept 2024Canaccord GenuityMaintainsBuy—
23 Sept 2024JefferiesDowngradeHold—
11 July 2024Piper SandlerMaintainsOverweight—
13 June 2024Piper SandlerMaintainsOverweight—
12 Apr 2024Canaccord GenuityMaintainsBuy—
8 Apr 2024Piper SandlerMaintainsOverweight—
28 Feb 2024JP MorganMaintainsOverweight—
17 Nov 2023Piper SandlerInitiatesOverweight—
9 Aug 2023JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PRGO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PRGO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Perrigo Co. Plc returned +35.2% against +12.2% for the S&P 500, dividends included.

PRGO vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26PRGOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PRGO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+7.1%
Analysts raising
2
Analysts cutting
0
Fundamentals

Perrigo Co. Plc (PRGO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2818.0×

Cheaper than 1% of US stocks

Price / sales
0.5×

Cheaper than 78% of US stocks

Price / book
0.9×

Cheaper than 72% of US stocks

EV / EBITDA
9.3×

Cheaper than 39% of US stocks

Growth & margins
Revenue growth (YoY)
−5.2%

Higher than 21% of US stocks

Earnings growth (YoY)
−3.2%

Higher than 33% of US stocks

Gross margin
30.7%

Higher than 35% of US stocks

Operating margin
5.5%

Higher than 57% of US stocks

Net margin
−43.3%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−50.2%

Higher than 21% of US stocks

Return on assets
1.6%

Higher than 55% of US stocks

Dividend yield
7.0%

Higher than 95% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Perrigo Co. Plc (PRGO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Perrigo Co. Plc has a market value of $2.2B and an enterprise value of $5.2B.

  • Revenue in the twelve months to 30 June 2026: $4.1B. The latest quarter shrank 5.2% year on year.

  • Net income over the same four quarters: −$1.7B, a −41.9% net margin.

  • Diluted earnings per share, trailing twelve months: −$12.51.

  • Free cash flow in the twelve months to 30 June 2026: $119.3M.

  • Perrigo Co. Plc spent $159.9M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 138.7M.

  • Trailing P/E: 2818.0×; forward P/E: 6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 7.05%, paying out 1349% of earnings.

  • Perrigo Co. Plc employs 8,100 people — $512K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

PRGO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PRGOPerrigo Co. Plc$2.2B90
RGCRegencell Bioscience Holdings Ltd.$2.3B22
PBHPrestige Consumer Healthcare, Inc.$2.3B57
SUPNSupernus Pharmaceuticals, Inc.$2.4B—
TRLVTrulieve Cannabis Corp.$1.9B71
BCRXBioCryst Pharmaceuticals, Inc.$1.9B82
ETONEton Pharmaceuticals, Inc.$1.8B99

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Perrigo Co. Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRGO news & analysis

Perrigo to Attend the Jefferies Miami Consumer Conference

PRNewsWire · 11 Nov 2026neutral

Perrigo said Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Jefferies Miami Consumer Conference on November 18, 2026.

Why it matters — The announcement informs PRGO watchers that the company’s interim CEO and CFO are scheduled to meet with investors at the conference.

Perrigo Q3 Earnings Call Highlights

MarketBeat · 8 Nov 2026negative

Perrigo reported lower third-quarter sales and earnings, citing cautious retailer inventory decisions and weakness in Europe. The company also gained market share and narrowed its core sales decline.

Why it matters — The results show how retailer inventory choices and European weakness affected PRGO, alongside market-share gains and a narrower core sales decline.

Perrigo: 3 Key Takeaways for Long-Term Investors

The Motley Fool · 7 Nov 2026neutral

Perrigo agreed to divest its infant formula business, and U.S. e-commerce reached 22% of the company’s U.S. volume.

Why it matters — These developments provide PRGO watchers with updates on the company’s portfolio and U.S. sales channels.

Perrigo Company plc (PRGO) Q3 2026 Earnings Call Transcript

Seeking Alpha · 4 Nov 2026neutral

Perrigo held its third-quarter 2026 financial results conference call on November 4, 2026. The excerpt identifies company representatives and call participants but does not provide financial results or management commentary.

Why it matters — The transcript listing signals a quarterly results discussion, but the excerpt offers no details on performance or outlook for PRGO watchers to assess.

Perrigo (PRGO) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 4 Nov 2026neutral

Zacks Investment Research says Perrigo’s headline Q3 earnings numbers offer a view of its performance in the quarter ended September 2026. The excerpt suggests comparing key metrics with Wall Street estimates and year-ago actuals.

Why it matters — Those comparisons provide context for assessing Perrigo’s quarterly performance.

FAQ

Frequently asked questions about PRGO stock

What is the PRGO stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Perrigo Co. Plc have a median 12-month price target of $19, with estimates ranging from $15 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PRGO stock a buy right now?

Of the 4 analysts covering Perrigo Co. Plc, 1 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Perrigo Co. Plc 90 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRGO?

As at 17 Nov 2026, Perrigo Co. Plc ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).

Will PRGO stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +12.2% from the last close, and Ticker Nerd's factor model ranks Perrigo Co. Plc 90 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PRGO stock forecast for 2030?

No analyst covering Perrigo Co. Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $20 over the next 12 months.

How has PRGO stock performed over the past year?

Perrigo Co. Plc returned +35.2% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Perrigo Co. Plc do?

Perrigo Company plc is a consumer health company that develops, manufactures, and markets self-care products and over-the-counter health and wellness solutions. Its portfolio spans products for everyday needs such as pain relief, digestive health, allergy care, cough and cold, nutrition, and infant care, serving consumers through branded and store-brand offerings.

What is the latest news on PRGO?

The most recent item we track (PRNewsWire, 11 Nov 2026): "Perrigo to Attend the Jefferies Miami Consumer Conference". Perrigo said Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Jefferies Miami Consumer Conference on November 18, 2026.

Company

About Perrigo Co. Plc.

Perrigo Company plc is a consumer health company that develops, manufactures, and markets self-care products and over-the-counter health and wellness solutions. Its portfolio spans products for everyday needs such as pain relief, digestive health, allergy care, cough and cold, nutrition, and infant care, serving consumers through branded and store-brand offerings. The company also participates in selected prescription pharmaceutical and active ingredient businesses, giving it a broader presence across healthcare supply chains. Perrigo Company plc focuses on accessible, self-managed healthcare products that are distributed across the United States, Europe, and other international markets. Headquartered in Dublin, Ireland, Perrigo Company plc plays a significant role in the consumer health market by supplying large retailers, pharmacies, and healthcare channels with products designed for routine, non-prescription use.

CEO Mr. Albert Ange Manzone · 8,100 employees · Ireland · https://www.perrigo.com